The Experts below are selected from a list of 159120 Experts worldwide ranked by ideXlab platform

C W J Melling - One of the best experts on this subject based on the ideXlab platform.

  • the effects of exercise training versus intensive Insulin Treatment on skeletal muscle fibre content in type 1 diabetes mellitus rodents
    Lipids in Health and Disease, 2021
    Co-Authors: David P Mcbey, Michelle S Dotzert, C W J Melling
    Abstract:

    Intensive-Insulin Treatment (IIT) strategy for patients with type 1 diabetes mellitus (T1DM) has been associated with sedentary behaviour and the development of Insulin resistance. Exercising patients with T1DM often utilize a conventional Insulin Treatment (CIT) strategy leading to increased Insulin sensitivity through improved intramyocellular lipid (IMCL) content. It is unclear how these exercise-related metabolic adaptations in response to exercise training relate to individual fibre-type transitions, and whether these alterations are evident between different Insulin strategies (CIT vs. IIT). Purpose: This study examined glycogen and fat content in skeletal muscle fibres of diabetic rats following exercise-training. Male Sprague-Dawley rats were divided into four groups: Control-Sedentary, CIT- and IIT-treated diabetic sedentary, and CIT-exercised trained (aerobic/resistance; DARE). After 12 weeks, muscle-fibre lipids and glycogen were compared through immunohistochemical analysis. The primary findings were that both IIT and DARE led to significant increases in type I fibres when compared to CIT, while DARE led to significantly increased lipid content in type I fibres compared to IIT. These findings indicate that alterations in lipid content with Insulin Treatment and DARE are primarily evident in type I fibres, suggesting that muscle lipotoxicity in type 1 diabetes is muscle fibre-type dependant.

  • The effects of exercise training versus intensive Insulin Treatment on skeletal muscle fibre content in type 1 diabetes mellitus rodents
    'Springer Science and Business Media LLC', 2021
    Co-Authors: David P Mcbey, Michelle S Dotzert, C W J Melling
    Abstract:

    Abstract Background Intensive-Insulin Treatment (IIT) strategy for patients with type 1 diabetes mellitus (T1DM) has been associated with sedentary behaviour and the development of Insulin resistance. Exercising patients with T1DM often utilize a conventional Insulin Treatment (CIT) strategy leading to increased Insulin sensitivity through improved intramyocellular lipid (IMCL) content. It is unclear how these exercise-related metabolic adaptations in response to exercise training relate to individual fibre-type transitions, and whether these alterations are evident between different Insulin strategies (CIT vs. IIT). Purpose: This study examined glycogen and fat content in skeletal muscle fibres of diabetic rats following exercise-training. Methods Male Sprague-Dawley rats were divided into four groups: Control-Sedentary, CIT- and IIT-treated diabetic sedentary, and CIT-exercised trained (aerobic/resistance; DARE). After 12 weeks, muscle-fibre lipids and glycogen were compared through immunohistochemical analysis. Results The primary findings were that both IIT and DARE led to significant increases in type I fibres when compared to CIT, while DARE led to significantly increased lipid content in type I fibres compared to IIT. Conclusions These findings indicate that alterations in lipid content with Insulin Treatment and DARE are primarily evident in type I fibres, suggesting that muscle lipotoxicity in type 1 diabetes is muscle fibre-type dependant

Marc G Jeschke - One of the best experts on this subject based on the ideXlab platform.

  • stress hyperglycemia Insulin Treatment and innate immune cells
    International Journal of Endocrinology, 2014
    Co-Authors: Mile Stanojcic, Li Diao, Marc G Jeschke
    Abstract:

    Hyperglycemia (HG) and Insulin resistance are the hallmarks of a profoundly altered metabolism in critical illness resulting from the release of cortisol, catecholamines, and cytokines, as well as glucagon and growth hormone. Recent studies have proposed a fundamental role of the immune system towards the development of Insulin resistance in traumatic patients. A comprehensive review of published literatures on the effects of hyperglycemia and Insulin on innate immunity in critical illness was conducted. This review explored the interaction between the innate immune system and trauma-induced hypermetabolism, while providing greater insight into unraveling the relationship between innate immune cells and hyperglycemia. Critical illness substantially disturbs glucose metabolism resulting in a state of hyperglycemia. Alterations in glucose and Insulin regulation affect the immune function of cellular components comprising the innate immunity system. Innate immune system dysfunction via hyperglycemia is associated with a higher morbidity and mortality in critical illness. Along with others, we hypothesize that reduction in morbidity and mortality observed in patients receiving Insulin Treatment is partially due to its effect on the attenuation of the immune response. However, there still remains substantial controversy regarding moderate versus intensive Insulin Treatment. Future studies need to determine the integrated effects of HG and Insulin on the regulation of innate immunity in order to provide more effective Insulin Treatment regimen for these patients.

  • Insulin Treatment improves the systemic inflammatory reaction to severe trauma
    Annals of Surgery, 2004
    Co-Authors: Marc G Jeschke, Dagmar Klein, David N Herndon
    Abstract:

    Objective:Determine the effect of Insulin on the systemic inflammatory response, pro- and anti-inflammatory cytokines and hepatic acute-phase-response in severely burned pediatric patients.Summary Background Data:The systemic inflammatory and hepatic acute-phase-response contribute to hypermetabolis

Wu Yangfeng - One of the best experts on this subject based on the ideXlab platform.

  • Observational Registry of Basal Insulin Treatment (ORBIT) in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs: real-life use of basal Insulin in China
    'Wiley', 2017
    Co-Authors: Ji Linong, Zhang Puhong, Zhu Dongshan, Li Xian, Ji Jiachao, Guo Xiaohui, Lu Juming, Jia Weiping, Weng Jianping, Wu Yangfeng
    Abstract:

    Aims: To examine Treatment patterns following basal Insulin (BI) introduction in type 2 diabetes mellitus (T2DM) patients under real-world conditions across China.Materials and methods: Overall, 18 995 patients inadequately controlled (HbA1c >= 53 mmol/mol [7%]) with oral antihyperglycaemic drugs (OADs) and willing to receive BI Treatment were registered at 209 hospitals and followed at baseline (visit 1), 3 months (visit 2) and 6 months (visit 3). Type of BI was initiated at physicians' discretion.Results: Retention with BI therapy at 6 months was 75.6%. Use of long-acting BI predominated, with Insulin glargine accounting for 71%, detemir 13% and Neutral Protamine Hagedorn (NPH) Insulin 16%. Over 70% of long-acting users maintained the same initial BI at visit 3, while 40% of NPH users switched Treatment and 24.4% of participants initiated BI with prandial Insulin. The initial mean (+/- SD) dose of BI and total Insulin was 0.18 +/- 0.07 and 0.25 +/- 0.19 IU/kg, respectively, with a mean increase of daily dose by 0.03 and 0.02 IU/kg after 6 months, respectively. Only 56.6% of Insulin users reported dose titration at visit 3. Mean HbA1c was 81 mmol/mol (9.6%) at baseline and 57 mmol/mol (7.4%) at 6 months. The frequency of hypoglycaemia was 1.61 and 2.07 episodes/patient-year at baseline and 6 months, respectively.Conclusions: In real-world clinical settings, add-on BI therapy in T2DM patients is associated with significant improvement in glycaemic control without overtly compromising safety related to hypoglycaemia and weight gain. Evolution of Insulin Treatment regimens varied among patients, but dose titration was suboptimal. More active BI dose titration might further improve glycaemic outcome in patients receiving BI therapy

  • Observational Registry of Basal Insulin Treatment (ORBIT) in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs: Real-life use of basal Insulin in China
    DIABETES OBESITY & METABOLISM, 2017
    Co-Authors: Ji Linong, Zhang Puhong, Zhu Dongshan, Li Xian, Ji Jiachao, Guo Xiaohui, Lu Juming, Jia Weiping, Weng Jianping, Wu Yangfeng
    Abstract:

    Aims: To examine Treatment patterns following basal Insulin (BI) introduction in type 2 diabetes mellitus (T2DM) patients under real-world conditions across China. Materials and methods: Overall, 18 995 patients inadequately controlled (HbA1c >= 53 mmol/mol [7%]) with oral antihyperglycaemic drugs (OADs) and willing to receive BI Treatment were registered at 209 hospitals and followed at baseline (visit 1), 3 months (visit 2) and 6 months (visit 3). Type of BI was initiated at physicians' discretion. Results: Retention with BI therapy at 6 months was 75.6%. Use of long-acting BI predominated, with Insulin glargine accounting for 71%, detemir 13% and Neutral Protamine Hagedorn (NPH) Insulin 16%. Over 70% of long-acting users maintained the same initial BI at visit 3, while 40% of NPH users switched Treatment and 24.4% of participants initiated BI with prandial Insulin. The initial mean (+/- SD) dose of BI and total Insulin was 0.18 +/- 0.07 and 0.25 +/- 0.19 IU/kg, respectively, with a mean increase of daily dose by 0.03 and 0.02 IU/kg after 6 months, respectively. Only 56.6% of Insulin users reported dose titration at visit 3. Mean HbA1c was 81 mmol/mol (9.6%) at baseline and 57 mmol/mol (7.4%) at 6 months. The frequency of hypoglycaemia was 1.61 and 2.07 episodes/patient-year at baseline and 6 months, respectively. Conclusions: In real-world clinical settings, add-on BI therapy in T2DM patients is associated with significant improvement in glycaemic control without overtly compromising safety related to hypoglycaemia and weight gain. Evolution of Insulin Treatment regimens varied among patients, but dose titration was suboptimal. More active BI dose titration might further improve glycaemic outcome in patients receiving BI therapy.Sanofi-Aventis (Shanghai, China)SCI(E)ARTICLE6822-8301

David P Mcbey - One of the best experts on this subject based on the ideXlab platform.

  • the effects of exercise training versus intensive Insulin Treatment on skeletal muscle fibre content in type 1 diabetes mellitus rodents
    Lipids in Health and Disease, 2021
    Co-Authors: David P Mcbey, Michelle S Dotzert, C W J Melling
    Abstract:

    Intensive-Insulin Treatment (IIT) strategy for patients with type 1 diabetes mellitus (T1DM) has been associated with sedentary behaviour and the development of Insulin resistance. Exercising patients with T1DM often utilize a conventional Insulin Treatment (CIT) strategy leading to increased Insulin sensitivity through improved intramyocellular lipid (IMCL) content. It is unclear how these exercise-related metabolic adaptations in response to exercise training relate to individual fibre-type transitions, and whether these alterations are evident between different Insulin strategies (CIT vs. IIT). Purpose: This study examined glycogen and fat content in skeletal muscle fibres of diabetic rats following exercise-training. Male Sprague-Dawley rats were divided into four groups: Control-Sedentary, CIT- and IIT-treated diabetic sedentary, and CIT-exercised trained (aerobic/resistance; DARE). After 12 weeks, muscle-fibre lipids and glycogen were compared through immunohistochemical analysis. The primary findings were that both IIT and DARE led to significant increases in type I fibres when compared to CIT, while DARE led to significantly increased lipid content in type I fibres compared to IIT. These findings indicate that alterations in lipid content with Insulin Treatment and DARE are primarily evident in type I fibres, suggesting that muscle lipotoxicity in type 1 diabetes is muscle fibre-type dependant.

  • The effects of exercise training versus intensive Insulin Treatment on skeletal muscle fibre content in type 1 diabetes mellitus rodents
    'Springer Science and Business Media LLC', 2021
    Co-Authors: David P Mcbey, Michelle S Dotzert, C W J Melling
    Abstract:

    Abstract Background Intensive-Insulin Treatment (IIT) strategy for patients with type 1 diabetes mellitus (T1DM) has been associated with sedentary behaviour and the development of Insulin resistance. Exercising patients with T1DM often utilize a conventional Insulin Treatment (CIT) strategy leading to increased Insulin sensitivity through improved intramyocellular lipid (IMCL) content. It is unclear how these exercise-related metabolic adaptations in response to exercise training relate to individual fibre-type transitions, and whether these alterations are evident between different Insulin strategies (CIT vs. IIT). Purpose: This study examined glycogen and fat content in skeletal muscle fibres of diabetic rats following exercise-training. Methods Male Sprague-Dawley rats were divided into four groups: Control-Sedentary, CIT- and IIT-treated diabetic sedentary, and CIT-exercised trained (aerobic/resistance; DARE). After 12 weeks, muscle-fibre lipids and glycogen were compared through immunohistochemical analysis. Results The primary findings were that both IIT and DARE led to significant increases in type I fibres when compared to CIT, while DARE led to significantly increased lipid content in type I fibres compared to IIT. Conclusions These findings indicate that alterations in lipid content with Insulin Treatment and DARE are primarily evident in type I fibres, suggesting that muscle lipotoxicity in type 1 diabetes is muscle fibre-type dependant

Ji Linong - One of the best experts on this subject based on the ideXlab platform.

  • Observational registry of basal Insulin Treatment in patients with type 2 diabetes in China: safety and hypoglycemia predictors
    'Mary Ann Liebert Inc', 2017
    Co-Authors: Zhang Tingting, Ji Linong, Gao Yan, Zhang Puhong, Zhu Dongshan, Li Xian, Ji Jiachao, Zhao Fang, Zhang Heng, Guo Xiaohui
    Abstract:

    Background: The Observational Registry of Basal Insulin Treatment (ORBIT) study evaluated the safety of basal Insulin (BI) in real-world settings in China. Methods: We analyzed 9002 patients with type 2 diabetes (T2D) inadequately controlled with oral hypoglycemic agents from 8 geographic regions and 2 hospital tiers in China who initiated and maintained BI Treatment. Body weight and hypoglycemic episodes were recorded at baseline and 3 and 6 months. Serious adverse events (SAEs) were recorded at 3 and 6 months. Results: Age, gender, inpatient/outpatient status, body mass index, glycated hemoglobin (HbA1c) at baseline and at the end of study, T2D duration, microvascular complications, BI type, combination with Insulin secretagogues, self-monitoring of blood glucose frequency, and Insulin dosage, all predicted hypoglycemia. BI use generally did not induce significant weight gain (0.02kg); weight gain with Insulin detemir (-0.30kg) was less than that with neutral protamine Hagedorn (NPH) Insulin (0.20kg) or Insulin glargine (0.05kg). Overall, general hypoglycemia incidence (5.6% vs. 7.7%) and annual event rate (1.6 vs. 1.8) were similar before and after BI initiation, whereas a slight decrease was noted in severe hypoglycemia incidence (0.6%-0.3%) and frequency (0.05-0.03 events/patient-year). The general hypoglycemia rate was lowest with Insulin glargine, whereas there was no significant difference in severe hypoglycemia among the three BI groups. Overall, 3.5% of patients had at least one SAE during the study. Most SAEs were found to be unrelated to BI Treatment. Conclusions: Real-world BI use, particularly Insulin detemir and glargine, was associated with only slight weight gain and low hypoglycemia risk in patients with T2D in China

  • Observational Registry of Basal Insulin Treatment (ORBIT) in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs: real-life use of basal Insulin in China
    'Wiley', 2017
    Co-Authors: Ji Linong, Zhang Puhong, Zhu Dongshan, Li Xian, Ji Jiachao, Guo Xiaohui, Lu Juming, Jia Weiping, Weng Jianping, Wu Yangfeng
    Abstract:

    Aims: To examine Treatment patterns following basal Insulin (BI) introduction in type 2 diabetes mellitus (T2DM) patients under real-world conditions across China.Materials and methods: Overall, 18 995 patients inadequately controlled (HbA1c >= 53 mmol/mol [7%]) with oral antihyperglycaemic drugs (OADs) and willing to receive BI Treatment were registered at 209 hospitals and followed at baseline (visit 1), 3 months (visit 2) and 6 months (visit 3). Type of BI was initiated at physicians' discretion.Results: Retention with BI therapy at 6 months was 75.6%. Use of long-acting BI predominated, with Insulin glargine accounting for 71%, detemir 13% and Neutral Protamine Hagedorn (NPH) Insulin 16%. Over 70% of long-acting users maintained the same initial BI at visit 3, while 40% of NPH users switched Treatment and 24.4% of participants initiated BI with prandial Insulin. The initial mean (+/- SD) dose of BI and total Insulin was 0.18 +/- 0.07 and 0.25 +/- 0.19 IU/kg, respectively, with a mean increase of daily dose by 0.03 and 0.02 IU/kg after 6 months, respectively. Only 56.6% of Insulin users reported dose titration at visit 3. Mean HbA1c was 81 mmol/mol (9.6%) at baseline and 57 mmol/mol (7.4%) at 6 months. The frequency of hypoglycaemia was 1.61 and 2.07 episodes/patient-year at baseline and 6 months, respectively.Conclusions: In real-world clinical settings, add-on BI therapy in T2DM patients is associated with significant improvement in glycaemic control without overtly compromising safety related to hypoglycaemia and weight gain. Evolution of Insulin Treatment regimens varied among patients, but dose titration was suboptimal. More active BI dose titration might further improve glycaemic outcome in patients receiving BI therapy

  • Observational Registry of Basal Insulin Treatment (ORBIT) in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs: Real-life use of basal Insulin in China
    DIABETES OBESITY & METABOLISM, 2017
    Co-Authors: Ji Linong, Zhang Puhong, Zhu Dongshan, Li Xian, Ji Jiachao, Guo Xiaohui, Lu Juming, Jia Weiping, Weng Jianping, Wu Yangfeng
    Abstract:

    Aims: To examine Treatment patterns following basal Insulin (BI) introduction in type 2 diabetes mellitus (T2DM) patients under real-world conditions across China. Materials and methods: Overall, 18 995 patients inadequately controlled (HbA1c >= 53 mmol/mol [7%]) with oral antihyperglycaemic drugs (OADs) and willing to receive BI Treatment were registered at 209 hospitals and followed at baseline (visit 1), 3 months (visit 2) and 6 months (visit 3). Type of BI was initiated at physicians' discretion. Results: Retention with BI therapy at 6 months was 75.6%. Use of long-acting BI predominated, with Insulin glargine accounting for 71%, detemir 13% and Neutral Protamine Hagedorn (NPH) Insulin 16%. Over 70% of long-acting users maintained the same initial BI at visit 3, while 40% of NPH users switched Treatment and 24.4% of participants initiated BI with prandial Insulin. The initial mean (+/- SD) dose of BI and total Insulin was 0.18 +/- 0.07 and 0.25 +/- 0.19 IU/kg, respectively, with a mean increase of daily dose by 0.03 and 0.02 IU/kg after 6 months, respectively. Only 56.6% of Insulin users reported dose titration at visit 3. Mean HbA1c was 81 mmol/mol (9.6%) at baseline and 57 mmol/mol (7.4%) at 6 months. The frequency of hypoglycaemia was 1.61 and 2.07 episodes/patient-year at baseline and 6 months, respectively. Conclusions: In real-world clinical settings, add-on BI therapy in T2DM patients is associated with significant improvement in glycaemic control without overtly compromising safety related to hypoglycaemia and weight gain. Evolution of Insulin Treatment regimens varied among patients, but dose titration was suboptimal. More active BI dose titration might further improve glycaemic outcome in patients receiving BI therapy.Sanofi-Aventis (Shanghai, China)SCI(E)ARTICLE6822-8301